Asian Pacific Journal of Cancer Prevention

  • 제13권5호
  • /
  • Pages.2051-2055
  • /
  • 2012
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

The CHEK2 I157T Variant and Colorectal Cancer Susceptibility: A Systematic Review and Meta-analysis

  • Liu, Chuan (Department of Oncology, Changhai Hospital, The Second Military Medical University) ;
  • Wang, Qing-Shui (Department of Oncology, Changhai Hospital, The Second Military Medical University) ;
  • Wang, Ya-Jie (Department of Oncology, Changhai Hospital, The Second Military Medical University)
  • 발행 : 2012.05.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: The cell cycle checkpoint kinase 2 (CHEK2) gene I157T variant may be associated with an increased risk of colorectal cancer, but it is unclear whether the evidence is sufficient to recommend testing for the mutation in clinical practice. Materials and Methods: We systematically searched PubMed, EMBASES, Elsevier and Springer for relevant articles before Apr 2012. Summary odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using a fixed-effects or random-effects models with Review Manager 5.0 software. Results: A total of seven studies including 4,029 cases and 13,844 controls based on the search criteria were included for analysis. A significant association of the CHEK2 I157T C variant with unselected CRC was found (OR = 1.61, 95% CI = 1.40-1.87, P < 0.001). We also found a significant association with sporadic CRC (OR = 1.48, 95% CI = 1.23-1.77, P < 0.001) and separately with familial CRC (OR = 1.97, 95% CI = 1.41-2.74, P < 0.001). Conclusion: This meta-analysis demonstrates that the CHEK2 I157T variant may be another important CRC-predisposing gene, which increases CRC risk, especially in familial CRC.

키워드

참고문헌

  1. Ahmedin J, Freddie B, Melissa M, et al (2011). Global Cancer Statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  2. Bartek J, Falck J, Lukas J (2001). CHK2 kinase: a busy messenger. Nat Rev Mol Cell Biol, 2, 877-86. https://doi.org/10.1038/35103059
  3. Bartek J, Lukas J (2001). Mammalian G1- and S- phase checkpoints in response to DNA damage. Curr Opin Cell Biol, 13, 738-47. https://doi.org/10.1016/S0955-0674(00)00280-5
  4. Bartek J, Lukas J (2003). Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell, 3, 421-9. https://doi.org/10.1016/S1535-6108(03)00110-7
  5. Barone M, Lofano K, De Tullio N, et al (2012). Dietary, endocrine, and metabolic factors in the development of colorectal cancer. J Gastrointest Cancer, 43, 13-9.
  6. Bell DW, Varley JM, Szydlo TE et al (1999) Heterozygous germ line CHK2 mutations in Li-Fraumeni syndrome. Science, 286, 2528-31. https://doi.org/10.1126/science.286.5449.2528
  7. Brennan P, McKay J, Moore L, et al (2007). Uncommon CHEK2 missense variant and reduced risk of tobacco-related cancers: case control study. Hum Mol Genet, 16, 1794-801. https://doi.org/10.1093/hmg/ddm127
  8. Chaturvedi P, Eng WK, Zhu Y, et al (1999). Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene, 18, 4047-54. https://doi.org/10.1038/sj.onc.1202925
  9. Chehab NH, Malikzay A, Appel M, et al (2000). Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53. Genes Dev, 14, 278-88.
  10. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29. https://doi.org/10.2307/3001666
  11. Cybulski C, Gorski B, Huzarski T, et al (2004). CHEK2 is a multi-organ cancer susceptibility gene. Am J Hum Genet, 75, 1131-5. https://doi.org/10.1086/426403
  12. Cybulski C, Huzarski T, Gorski B et al (2004). A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res, 64, 2677-9. https://doi.org/10.1158/0008-5472.CAN-04-0341
  13. Cybulski C, Wokolorczyk D, Kladny J, et al (2007). Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations? Eur J Hum Genet, 15, 237-41. https://doi.org/10.1038/sj.ejhg.5201734
  14. Der Simonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  15. Domagala P, Wokolorczyk D, Cybulski C, et al (2012). Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer. Breast Cancer Res Treat, 132, 937-45. https://doi.org/10.1007/s10549-011-1635-7
  16. Egger M, Davey SG, Schneider M et al (1997). Bias in metaanalysis detected by a simple, graphical test. Br Med J, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  17. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
  18. Hutter CM, Chang-Claude J, Slattery ML, et al (2012). Characterization of gene-environment interactions for colorectal cancer susceptibility loci. Cancer Res, 72, 2036-44. https://doi.org/10.1158/0008-5472.CAN-11-4067
  19. Irmejs A, Miklasevics E, Boroschenko V, et al (2006). Pilot study on low penetrance breast and colorectal cancer predisposition markers in latvia. Hered Cancer Clin Pract, 4, 48-51. https://doi.org/10.1186/1897-4287-4-1-48
  20. Kilpivaara O, Alhopuro P, Vahteristo P, et al (2006). CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet, 43, e34.
  21. Kilpivaara O, Vahteristo P, Falck J, et al (2004). CHEK2 variant I157 may be associated with increased breast cancer risk. Int J Cancer, 111, 543-7. https://doi.org/10.1002/ijc.20299
  22. Kleibl Z, Havranek O, Hlavata I, et al (2009). The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population. Eur J Cancer, 45, 618-24. https://doi.org/10.1016/j.ejca.2008.09.022
  23. Knudson AG (2001). Hereditary cancer: Two hits revisited. J Cancer Res Clin Oncol, 122, 135-40.
  24. Konstantinova D, Kadiyska T, Sokolova V, et al (2010). CHEK2 I157T and colorectal cancer in Bulgaria. J BUON, 15, 314-7.
  25. Kuusisto KM, Bebel A, Vihinen M, et al (2011). Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res, 28, R20.
  26. Kuchiba A, Morikawa T, Yamauchi M, et al (2012). Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study. J Natl Cancer Inst, 104, 415-20. https://doi.org/10.1093/jnci/djr542
  27. Lichtenstein P, Holm NV, Holm PK, et al (2000). Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med, 343, 78-84. https://doi.org/10.1056/NEJM200007133430201
  28. Lizis-Kolus K, Kowalska A, Kozak-Klonowska B, et al (2010). Case report of a woman with monoclonal gammapathy and papillary thyroid carcinoma, diagnosed because of detection of CHEK2 (I157T) mutation in genetic examinations. Endokrynol Pol, 61, 502-6.
  29. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  30. Rowan AJ, Lamlum H, IIyas M, et al (2000). APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits". PNAS, 97, 3352-7. https://doi.org/10.1073/pnas.97.7.3352
  31. Scharrer U, Skrzypczak-Zielinsk M, Wituszynska W, et al (2010). A simple method of investigating mutations in CHEK2 by DHPLC: a study of the German populations of Saxony, Saxony-Anhalt, and Thuringia. Cancer Genet Cytogenet, 199, 48-52. https://doi.org/10.1016/j.cancergencyto.2009.11.015
  32. Suchy J, Cybulski C, Wokolorczyk D, et al (2010). CHEK2 mutations and HNPCC-related colorectal cancer. Int J Cancer, 126, 3005-9.
  33. Tischkowitz MD, Yilmaz A, Chen LQ, et al (2008). Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. Cancer Lett, 18, 173-80.
  34. Tomlinson IP, Houlston RS, Montgomery GW, et al (2012). Investigation of the effects of DNA repair gene polymorphisms on the risk of colorectal cancer. Mutagenesis, 27, 219-23. https://doi.org/10.1093/mutage/ger070
  35. Turnbull C, Seal S, Renwick A, et al (2012). Gene-gene interactions in breast cancer susceptibility. Hum Mol Genet, 21, 958-62. https://doi.org/10.1093/hmg/ddr525
  36. Weischer M, Bojesen SE, Ellervik C, et al (2008). CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol, 26, 542-8. https://doi.org/10.1200/JCO.2007.12.5922
  37. Xiang HP, Geng XP , Ge WW, et al (2011). Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility. EUR J Cancer, 47, 2546-51. https://doi.org/10.1016/j.ejca.2011.03.025
  38. zur Hausen H (2012). Red meat consumption and cancer: reasons to suspect involvement of bovine infectious factors in colorectal cancer. Int J Cancer, 130, 2475-83. https://doi.org/10.1002/ijc.27413

피인용 문헌

  1. Lack of CHEK2 Gene Mutations in Differentiated Thyroid Carcinoma Patients using High Resolution Melting Analysis vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.5019
  2. 1100delC Mutation and Risk of Prostate Cancer vol.2014, pp.2090-312X, 2014, https://doi.org/10.1155/2014/294575
  3. Modern methods in breast cancer diagnostics vol.8, pp.4, 2014, https://doi.org/10.1134/S1990750814040106
  4. Expanding the genotype–phenotype spectrum in hereditary colorectal cancer by gene panel testing vol.16, pp.2, 2017, https://doi.org/10.1007/s10689-016-9934-0
  5. Associations between mutations of the cell cycle checkpoint kinase 2 gene and gastric carcinogenesis vol.16, pp.4, 2017, https://doi.org/10.3892/mmr.2017.7080
  6. A counseling framework for moderate-penetrance colorectal cancer susceptibility genes pp.1530-0366, 2018, https://doi.org/10.1038/gim.2018.12
  7. Cancer genetics, precision prevention and a call to action vol.50, pp.9, 2018, https://doi.org/10.1038/s41588-018-0202-0
  8. Spectrum of APC and MUTYH germ-line mutations in Russian patients with colorectal malignancies vol.93, pp.5, 2018, https://doi.org/10.1111/cge.13228
  9. Managing Patient with Mutations in PALB2, CHEK2, or ATM vol.10, pp.2, 2018, https://doi.org/10.1007/s12609-018-0269-8